Inito, the India-based health tech startup founded by Aayush Rai and Varun AV in 2015, has secured $6M in Series A funding led by Fireside Ventures. The fresh funds will go towards global expansion of Inito’s hormone testing solutions and will bolster research and development efforts for new diagnostic tests.
Inito’s fertility monitor enables women to track fertility hormones quickly and conveniently from their homes. In contrast to conventional at-home ovulation tests, which predominantly focus on estrogen and Luteinizing hormone (LH), Inito’s monitor measures four fertility hormones on a single test strip: estrogen, LH, progesterone metabolite PdG, and FSH. Users globally have reported over 10,000 pregnancies and conducted more than 2.5 million tests using Inito’s solutions, according to the company.
The fertility monitor starter kit, priced at $149, comprises the device and 15 test strips, making it accessible to a broad user base. The monitor seamlessly connects to smartphones, offering step-by-step instructions through the Inito app and delivering personalized results based on individual hormonal profiles. This approach offers not just numerical values for fertility hormones but also provides insights into the full fertile window of six days and confirms ovulation through the rise in progesterone metabolite PdG.
Inito’s founders, Aayush Rai and Varun AV, have a vision focused on democratizing access to healthcare information. Their goal is to offer a wide range of at-home diagnostic tests for various health concerns through a single application, effectively placing healthcare in the hands of individuals.
With the recent injection of $6M in Series A funding, Inito is gearing up for significant expansion and innovation. The funds will be allocated to support the global expansion of its hormone tests and develop advanced analytics tools harnessing artificial intelligence. Additionally, Inito intends to invest in research and development for new diagnostic tests.
This recent funding round brings Inito’s total funding to date to $15M. Prior to this Series A round, the startup had already secured $9M in funding from notable investors, including Y Combinator, former Nurx CEO Varsha Rao, and a group of physicians and family offices.
